Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
BACKGROUND
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are widely used for the treatment of hypercholesterolemia and coronary heart disease and for the prevention of stroke. There have been various adverse effects, most commonly affecting muscle and ranging from myalgia to rhabdomyolysis. These adverse effects may be due to a coenzyme Q(10) (CoQ(10)) deficiency because inhibition of cholesterol biosynthesis also inhibits the synthesis of CoQ(10).


OBJECTIVE
To measure CoQ(10) levels in blood from hypercholesterolemic subjects before and after exposure to atorvastatin calcium, 80 mg/d, for 14 and 30 days.


METHODS
Prospective blinded study of the effects of short-term exposure to atorvastatin on blood levels of CoQ(10).


METHODS
Stroke center at an academic tertiary care hospital. Patients We examined a cohort of 34 subjects eligible for statin treatment according to National Cholesterol Education Program: Adult Treatment Panel III criteria.


RESULTS
The mean +/- SD blood concentration of CoQ(10) was 1.26 +/- 0.47 micro g/mL at baseline, and decreased to 0.62 +/- 0.39 micro g/mL after 30 days of atorvastatin therapy (P<.001). A significant decrease was already detectable after 14 days of treatment (P<.001).


CONCLUSIONS
Even brief exposure to atorvastatin causes a marked decrease in blood CoQ(10) concentration. Widespread inhibition of CoQ(10) synthesis could explain the most commonly reported adverse effects of statins, especially exercise intolerance, myalgia, and myoglobinuria.
Rundek
Tatjana
T
Department of Neurology, Columbia University College of Physicians & Surgeons, New York, NY 10032, USA.
Naini
Ali
A
Sacco
Ralph
R
Coates
Kristen
K
DiMauro
Salvatore
S
D000368:Aged; D000704:Analysis of Variance; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000097:blood* / Q000188:drug therapy; D003067:Coenzymes; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors; D020521:Stroke / Q000097:blood* / Q000188:drug therapy; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000097:blood*
D003067:Coenzymes; D006538:Heptanoic Acids; D011758:Pyrroles; D014451:Ubiquinone; D000069059:Atorvastatin; C024989:coenzyme Q10